newsfilter
← Latest News
GlobeNewswire·

Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC

Webcast will be held Tuesday, November 10, 2026, at 7:30 a.m. ET CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing